Immunocore (IMCR) Stock Analysis 2026: 96.5% Gross Margins, +103% Analyst Upside, and KIMMTRAK Growth Ahead of May 6 Earnings

Immunocore Holdings (NASDAQ: IMCR) is a clinical-stage-turned-commercial-stage biotechnology company that has achieved something rare in the orphan oncology space: FDA-approved revenue, 96.5% gross margins, and a trajectory toward EBITDA breakeven — all while trading at $31.45 against an analyst consensus target of $63.86. The Equity Rank model assigns IMCR a 75.3 SAVE score, a 59.5% combined margin of safety, and a low 34.6 risk score — the latter driven by 98.9% institutional ownership and a below-market beta of 0.832.

With earnings on May 6, 2026, this is the setup worth understanding now.

The KIMMTRAK Platform

Immunocore's lead asset, KIMMTRAK (tebentafusp), received FDA approval in January 2022 as the first T-cell receptor (TCR) bispecific therapy ever approved. It targets gp100, a peptide-HLA complex expressed by uveal melanoma cells, and redirects T-cells to destroy them.

Uveal melanoma is a rare, aggressive cancer with approximately 1,500 new U.S. cases per year and a historically dismal prognosis. Until KIMMTRAK, the median overall survival in metastatic disease was under 12 months. The Phase 3 IMCgp100-202 trial demonstrated a statistically significant overall survival benefit versus investigator's choice, earning KIMMTRAK its approval and Breakthrough Therapy designation.

This positions Immunocore as the category leader in a high-price, low-competition orphan oncology niche — a durable moat in pharmaceutical pricing.

Revenue Architecture: 96.5% Gross Margins Are No Accident

KIMMTRAK is priced in the orphan oncology range (~$800K+ per treatment course), which is why the financials look the way they do:

The 96.5% gross margin reflects near-zero cost of goods — KIMMTRAK is a biologics product with high upfront R&D sunk costs and minimal per-unit COGS. Once approved, the incremental economics are exceptional.

More important: EBITDA of −$22.4M on $400M revenue means Immunocore is operating at near-breakeven. The operating margin of 0.04% is essentially zero — the company is investing its gross profits into pipeline expansion, not funding structural losses.

EPS Trajectory: +822% YoY Improvement

The most telling metric is the quarterly EPS growth rate: +822% YoY improvement, reflecting EPS moving from deeply negative toward zero. This is the inflection investors pay for. The market is pricing IMCR as though it will remain perpetually loss-making; the data says otherwise.

Valuation: Why the Model Shows 59.5% Margin of Safety

Since IMCR has negative trailing EPS, no traditional P/E is applicable. The Equity Rank model defaults to asset-based and revenue-based methods:

The 59.5% combined margin of safety reflects the gap between $31.45 and model-estimated intrinsic value. The 75.3 SAVE score integrates revenue quality (96.5% gross margins), growth momentum (+24.3%), EPS improvement trajectory, and low systematic risk (beta 0.832).

The low 34.6 risk score — despite loss-making status — is driven by:

• 98.9% institutional ownership: Virtually no retail overhang; long-only funds and biotech specialists dominate the cap table
• Beta 0.832: Moves less than the market on average
• 52-week range $27.44–$40.71: Already proved support at $27; current $31.45 sits near the range midpoint

Analyst Consensus: 11 Overweight / 4 Hold, $63.86 Target

The $63.86 consensus target implies +103% upside from $31.45. Zero sell ratings. This level of analyst conviction is rare for a loss-making biotech — it reflects confidence in KIMMTRAK's commercial trajectory and pipeline optionality (ImmTAC platform extends beyond uveal melanoma into multiple tumor types and infectious disease).

The May 6 Earnings Catalyst

IMCR reports earnings on May 6, 2026. Key items to watch:

1. KIMMTRAK net product revenue: Consensus expects continued ~20%+ YoY growth. Any acceleration confirms commercial ramp.
2. EBITDA trajectory: A first positive EBITDA quarter would be a transformational catalyst. At current trajectory, Q1 or Q2 2026 is the likely first-positive window.
3. Pipeline updates: ImmTAC candidates for MAGE-A4 (multiple solid tumors) and HBV (hepatitis B) pipeline. Any Phase 2/3 readout materially expands the addressable market.
4. Guidance: Revenue guidance raise would trigger analyst target revisions upward.

Beta of 0.832 suggests muted macro sensitivity, but biotech stocks react sharply to clinical/commercial surprises. The direction is asymmetric: strong earnings could retest the 52-week high ($40.71) or break through; a miss at near-EBITDA breakeven could retest support at $27.

Pipeline Optionality: The ImmTAC Platform

KIMMTRAK is the first commercial proof of Immunocore's proprietary ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) platform. The platform is disease-agnostic — any peptide-HLA target is theoretically addressable.

Active pipeline beyond uveal melanoma includes:

• IMC-F106C: MAGE-A4 target in multiple solid tumors (non-small cell lung, esophageal, ovarian, bladder)
• IMCgp100-200 series: Expanded uveal melanoma regimens
• ImmTAV (infectious disease): HIV and HBV TCR bispecifics — a novel application of the platform in non-oncology

If even one ImmTAC candidate in a larger indication (NSCLC, for example) achieves Phase 3 data, the revenue addressable market expands by an order of magnitude beyond uveal melanoma's ~1,500 annual U.S. cases. This optionality is embedded in the $1.6B market cap.

Risk Factors

No trailing P/E available: EPS of −$0.71 TTM means traditional earnings-based valuation is inapplicable. The 59.5% MoS is model-estimated; it does not guarantee appreciation.

Orphan drug concentration risk: 100% of current revenue derives from KIMMTRAK in uveal melanoma. Any label change, competitive entry, or reimbursement pressure would disproportionately impact the business.

Path to profitability is not guaranteed: Operating margin of 0.04% means the company is at the edge of breakeven. A pipeline acceleration in spending could push EBITDA negative again before achieving sustained profitability.

Clinical trial risk: ImmTAC pipeline candidates have not yet demonstrated efficacy in broader indications. Phase 3 failures are common in oncology.

Forward P/E of 625x: At analyst consensus EPS estimates, the implied valuation requires significant EPS growth to be realized. This is a growth-at-reasonable-price thesis only if the EPS trajectory continues improving.

Small float: With only 45.1M shares in the float, IMCR is susceptible to volatile price movements on earnings surprises, analyst upgrades/downgrades, or clinical data releases.

Equity Rank SAVE Score Breakdown

Overall SAVE: 75.3 / 100. Risk score: 34.6 / 100 (lower = safer). Combined MoS: 59.5%.

Positioning Context

Immunocore sits in a unique intersection:

• Orphan drug moat: Category-first approval, ~$800K+ per patient pricing, minimal COGS
• Near-EBITDA breakeven: Not a speculative pre-revenue biotech; this is a commercialized drug approaching sustained profitability
• Platform optionality: ImmTAC extends into multiple tumor types and infectious disease
• Deep institutional backing: 98.9% institutional ownership at $31.45 implies sophisticated capital sees significant upside

The combination of 96.5% gross margins, +24.3% revenue growth, $63.86 analyst consensus, and low-beta profile makes IMCR one of the more compelling biotech setups in the screener ahead of its May 6 earnings date.

Tools to Run Your Own Analysis

Use the Equity Rank screener to compare IMCR against other biotechnology holdings. The EV/Revenue Calculator stress-tests current $400M revenue at 4x–8x EV/Revenue multiples — at 6x (biotech commercial median), implied market cap approaches $2.4B vs. the current $1.6B. The P/B Calculator shows the 4.19x P/B in context of the company's net asset base and pipeline investment.

This article is for informational and educational purposes only. Equity Rank is not a registered investment adviser. Nothing herein constitutes investment advice or a recommendation to purchase, hold, or sell Immunocore Holdings (IMCR) shares or any other security. IMCR currently reports negative trailing EPS (−$0.71 TTM); no trailing P/E is calculable, and the 75.3 SAVE score is based primarily on revenue-based and asset-based methods. The 59.5% combined margin of safety reflects the gap between current price and model-estimated intrinsic value; it is not a guarantee of price appreciation. Orphan drug revenue is concentrated in a single product (KIMMTRAK); any adverse clinical, regulatory, or reimbursement event could materially impair revenue. EPS improvement of +822% YoY reflects movement toward zero from deeply negative; the company may not achieve sustained GAAP profitability on the expected timeline. The analyst consensus target of $63.86 represents 11 Buy/Strong Buy and 4 Hold ratings; analyst estimates change frequently and may not be realized. The May 6, 2026 earnings release may move the stock materially. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Always conduct your own due diligence and consult a qualified financial professional before making investment decisions.